Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L D Jacobs

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Annals of Neurology|December 16, 2000
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research GroupJ S Fischer, R L Priore, L D Jacobs, et al.
Annals of Neurology|February 5, 1998
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupJ H Simon, L D Jacobs, M Campion, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 20, 2003
Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis ConsortiumB Weinstock-Guttman, L D Jacobs, C M Brownscheidle, et al.
Neurology|August 1, 1997
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, D E Goodkin, L D Jacobs, et al.
Annals of Neurology|March 1, 1996
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)L D Jacobs, D L Cookfair, R A Rudick, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 1999
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG)D E Goodkin, R L Priore, K E Wende, et al.
Journal of Neuroimmunology|June 23, 1999
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupR A Rudick, D L Cookfair, N A Simonian, et al.
Neurology|March 21, 2002
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997R A Rudick, D E Goodkin, L D Jacobs, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Annals of Neurology|December 16, 2000
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research GroupJ S Fischer, R L Priore, L D Jacobs, et al.
Annals of Neurology|February 5, 1998
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupJ H Simon, L D Jacobs, M Campion, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 20, 2003
Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis ConsortiumB Weinstock-Guttman, L D Jacobs, C M Brownscheidle, et al.
Neurology|August 1, 1997
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, D E Goodkin, L D Jacobs, et al.
Annals of Neurology|March 1, 1996
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)L D Jacobs, D L Cookfair, R A Rudick, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 1999
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG)D E Goodkin, R L Priore, K E Wende, et al.
Journal of Neuroimmunology|June 23, 1999
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupR A Rudick, D L Cookfair, N A Simonian, et al.
Neurology|March 21, 2002
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997R A Rudick, D E Goodkin, L D Jacobs, et al.
Pageof 4